N Engl J Med. 2005;353:1028-40.. AstraZeneca Announces European SEROQUEL XR Submission AstraZeneca has announced its submission of SEROQUEL XR to European regulatory authorities looking for authorization for both short-term and maintenance treatment of Generalised PANIC . This is actually the first-time acceptance offers been sought in European countries for an atypical antipsychotic medication for the treating GAD. The submission is founded on a robust clinical advancement programme involving a lot more than 3,500 sufferers in five Phase III safety and efficacy studies.Its role is to greatly help in creation of energy. It therefore leads to an intensified price of exercises and workout routines. It stimulates the muscle mass fibres to develop in strength and size and the results are noticeable in the bodybuilder’s ideal, compact body.. Chemists develop new laboratory check to examine how DNA harm disrupts protein synthesis Transcription is a cellular procedure by which genetic details from DNA is copied to messenger RNA for protein production. But anticancer medications and environmental chemicals can sometimes interrupt this movement of genetic information by causing modifications in DNA.